Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) wishes to clarify the nature of the supply arrangement by which Pharmadrug Production GmbH (“Pharmadrug”) is importing and distributing cannabis to pharmacies in Germany.

In a press release dated June 5th, 2019, the Company announced that Pharmadrug has ordered its second cannabis shipment from Bedrocan International B.V. (“Bedrocan”) and in a press release dated May 17th, 2019, the Company announced that Pharmadrug has supply agreements in place with Bedrocan. The Company wishes to clarify that Pharmadrug has no contractual relationship or supply agreements with Bedrocan. Pharmadrug has a supply relationship with The Netherlands Office of Medicinal Cannabis, to whom Bedrocan Netherlands, a wholly owned subsidiary of Bedrocan, acts as the exclusive supplier of medical cannabis.

The Company is excited to continue importing cannabis from the Netherlands and selling into the German market as it believes there is a tremendous opportunity to capitalize on favorable supply and demand dynamics.

About Aura Health Inc.

Aura Health is building an international network of vertically-integrated cannabis assets. The Company owns 80% of Pharmadrug, a German medical cannabis distributor, a convertible note to 54% of HolyCanna, a cultivation and nursery license holder in Israel, and has a binding LOI to purchase 57% of CannabiSendak, the builder of a network of dispensaries in Israel. Additionally, through significant extraction IP, Aura is dedicated to building a high-margin, downstream business of end-user products.

For further information, please contact:

Daniel Cohen, CEO Aura Health Inc. (647) 202-1824

David Posner, ChairmanAura Health Inc. (647) 985-6727

Deborah Honig, Investor RelationsAdelaide Capital Markets(647) 203-8793

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of Aura. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include reference to Aura’s marketing campaign, and the effectiveness of CanaCom, among others. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals, owning interests in companies or projects that are engaged in activities currently considered illegal under United States federal law; changes in laws; limited operating history, reliance on management, requirements for additional financing, competition, hindering market growth; regulatory and political change.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Pharmadrug (CSE:BUZZ)
過去 株価チャート
から 11 2024 まで 12 2024 Pharmadrugのチャートをもっと見るにはこちらをクリック
Pharmadrug (CSE:BUZZ)
過去 株価チャート
から 12 2023 まで 12 2024 Pharmadrugのチャートをもっと見るにはこちらをクリック